A British startup is pioneering pharmaceutical manufacturing in orbit, potentially reducing NHS costs by millions while delivering cancer treatments directly to patients' homes instead of hospital infusion centers.
BioOrbit launched Box-E, a microwave-sized unit, aboard a SpaceX flight from Kennedy Space Center in Florida to the International Space Station in May 2026. The compact device will spend approximately six weeks in microgravity, where weightlessness enables pharmaceutical compounds to crystallize into ultra-pure, highly stable structures impossible to achieve on Earth.
The innovation addresses a fundamental limitation of current cancer immunotherapies: their liquid formulations are too viscous for injection pens. By using space-grown protein crystals, BioOrbit can create concentrated formulations with low enough viscosity to flow through needles, transforming lengthy hospital infusions into self-administered injections patients can take at home or work.
The Science and Market Opportunity
Dr Katie King, co-founder and chief executive of BioOrbit, explained that gravity significantly impairs crystallization of large, flexible protein and antibody molecules. "Through going to space you see a much better, more superior crystallisation process than what you can achieve here on Earth," King said. The resulting crystals also extend drug shelf life, further improving home-based treatment feasibility.
Hundreds of experiments aboard the International Space Station have already validated the process. US pharmaceutical giant Merck produced protein crystals for its bestselling cancer medicine Keytruda, transforming it into a quick injection instead of lengthy IV infusion. The US health regulator approved this new delivery method in September 2025.
King argues that despite the substantial expense of space manufacturing, the shift to home-based therapy could save the NHS and other health systems "millions, potentially billions" of pounds by eliminating hospital visits, staff time, and facility costs.
Scaling Production and Investment
BioOrbit, founded in 2023 by King and medical doctor and cancer researcher Leonor Teles, raised £9.8 million from investors in May 2026, led by UK venture capital group LocalGlobe and Paris-based VC firm Breega. The company also won a £250,000 contract from the UK's Space Agency in March 2026 to advance its microgravity manufacturing technology.
Assuming successful orbital tests, multiple Box-E units can be stacked together to increase pharmaceutical production capacity. BioOrbit aims to process thousands of liters of fluid per box annually and estimates it could produce enough of a blockbuster drug with just a handful of boxes in continuous operation.
The commercial opportunity has attracted major industry attention. This week, Elon Musk's SpaceX outlined its stock market flotation prospectus, identifying in-space manufacturing of pharmaceuticals as a key revenue stream and estimating a $22.7 trillion market in enterprise applications. BioOrbit positions itself to capture significant market share in this emerging sector.
Timeline and Broader Applications
King cautioned that it will take at least five years before new cancer drug formulations reach patients, as they require clinical trials and regulatory approval from health authorities. The crystallization technology extends beyond cancer treatment, with approximately 70 percent of the world's biggest-selling drugs currently administered intravenously at hospitals or doctor's offices—all potential candidates for space-based reformulation.
BioOrbit plans to partner with pharmaceutical companies to manufacture its cancer drugs, and has already generated interest from several multinational groups in the UK and US. California-based competitor Varda Space Industries has also flown small capsules into space to process pharmaceuticals, currently working with US biotech United Therapeutics Corporation to develop improved treatments for rare lung disease.
Why This Matters:
This development demonstrates how private enterprise and market competition drive innovation in healthcare delivery and cost reduction. Rather than relying on government-funded research, a venture-backed startup identified a genuine market inefficiency—expensive hospital-based drug administration—and developed a technological solution. The potential savings to public health systems like the NHS represent significant fiscal benefits without requiring new government spending or regulatory mandates. The space manufacturing sector's emergence as a commercial venture, with SpaceX estimating a $22.7 trillion market opportunity, illustrates how private capital allocation efficiently identifies and funds high-impact applications. Success here could establish a model where market forces, not government planning, drive healthcare innovation and delivery improvements.